Marishka DeToy is a partner in Goodwin’s Life Sciences group and a member of the Capital Markets practice. She advises public and late-stage private life sciences companies on financing and strategic transactions and represents investment banks in capital markets offerings. Her financing experience includes initial public offerings, follow-on offerings, registered direct offerings, at-the-market offerings, PIPEs, and equity-linked offerings.
Marishka counsels companies as they prepare to enter the public markets and through subsequent capital raises and strategic transactions. She also advises boards of directors and senior management on corporate governance, SEC reporting and compliance, and ongoing corporate matters.
Experience
Marishka’s experience includes, among others, representation of:
Initial Public Offerings
- Black Diamond Therapeutics, Inc., in its $231.3 million initial public offering
- AgomAb Therapeutics NV in its $200 million initial public offering
- Prime Medicine, Inc., in its $175 million initial public offering
- Monte Rosa Therapeutics in its $222.3 million initial public offering
- Fusion Pharmaceuticals Inc. in its $212.5 million initial public offering
- Barinthus Biotherapeutics plc in its $110 million initial public offering
- Achilles Therapeutics plc in its $175.5 million initial public offering
- The underwriters in Omega Therapeutics’ $125.8 million initial public offering
- The underwriters in SQZ Biotechnologies Company’s $70 million initial public offering
- Goldman Sachs as lead underwriter in Taysha Gene Therapies, Inc.’s, $181 million initial public offering
- Bicycle Therapeutics plc in its $60 million initial public offering
- Kaleido Biosciences in its $75 million initial public offering
Other Capital Markets Transactions
- Rapport Therapeutics in its $380 million follow-on offering, convertible notes offering and concurrent private placement
- Black Diamond Therapeutics, Inc., in its $75 million follow-on offering
- Tango Therapeutics in its $690 million follow-on offering
- ProQR Therapeutics NV in its $50 million registered direct offering and $9.2 million concurrent private placement
- Prime Medicine, Inc. in its $161 million follow-on offering and $125 million follow-on offering
- CRISPR Therapeutics AG in its $280 million registered direct offering
- Amylyx Pharmaceuticals, Inc. in its $175 million follow-on offering and $60 million follow-on offering
- BeOne Medicines (formerly BeiGene) in its $3.5 billion initial public offering on STAR Market of the Shanghai Stock Exchange in China and redomiciliation into Switzerland
- BeOne in its $2.08 billion registered direct offering and $340 million follow-on offering
- Avadel Pharmaceuticals plc in its $65 million financing transaction, $125 million follow-on offering, $125 million follow-on offering, and $75 million synthetic royalty financing
- The underwriters in Vera Therapeutics’ $287.5 million follow-on offering, $300 million follow-on offering, and $261 million follow-on offering
- The underwriters in Myriad Genetics’ $110 million follow-on offering
- The underwriters in VSE Corporation’s $112.7 million follow-on offering
- BioDelivery Sciences International in its $60 million follow-on offering
- The underwriters in Alphatec’s $316.2 million convertible note offering
- argenx NV in its $557 million and $1.15 billion follow-on offerings
- The underwriters in Evelo Biosciences’ $72.6 million follow-on offering
- The underwriters in SQZ Biotechnologies Company’s $60 million follow-on offering
- scPharmaceuticals in its $50 million follow-on offering
- Celyad SA in its $20 million follow-on offering and $32.5 million private placement
- Aerpio Pharmaceuticals in its $45 million follow-on offering
Strategic Transactions
- Avadel Pharmaceuticals in its acquisition by Alkermes plc for $2.1 billion
- Barinthus Biotherapeutics plc in its definitive merger to combine with Clywedog Therapeutics, Inc., in an all-stock transaction
- IDRx, Inc., in its acquisition by GSK plc for $1 billion
- Barinthus Biotherapeutics (formerly Vaccitech) plc in its $40 million acquisition of Avidea Technologies
- Theseus Pharmaceuticals, Inc., in its definitive acquisition by Concentra Biosciences, LLC
- Alkermes Pharmaceuticals plc in the spinoff of its oncology business into Mural Oncology
- BioDelivery Sciences International in its definitive acquisition by Collegium Pharmaceutical for $604 million
- BeOne in its $2.7 billion global strategic collaboration with Amgen
Crossover and Private Financings
- Tubulis GbmH in its €400 million Series C financing
- IDRx, Inc., in its $120 million Series B financing
- AgomAb in its $89 million Series D financing
- Black Diamond Therapeutics, Inc., in its $85 million Series C financing
- Barinthus Biotherapeutics plc in its $168 million Series B financing
Credentials
Education
JD2015
Georgetown University Law Center
AB2009
Georgetown University
Admissions
Bars
- Massachusetts
- New York
Recognition & Awards
Marishka has been recognized as a “Next Generation Partner” in The Legal 500 2023-2026 in the Healthcare: Life Sciences category and as a recommended lawyer in the Capital Markets: Equity Offerings category.
Thought Leadership
- Speaker, LSX Europe IPO Bootcamp, April 2025
- Speaker, IPO Launchpad Panel, London, UK, November 2024
- Panelist, CFGI Capital Markets Roundtable, September 2024
- Speaker, LSX Europe IPO Bootcamp, April 2024
- IPO Bootcamp, London, UK, November 2023
- “Guide to the Initial Public Offering” publication in conjunction with Toppan Merrill, Fall 2023
